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The primary goal of tyrosine kinase inhibitor (TKI) therapy forpatients with chronic myeloid leukemia is survival, which isachieved by the vast majority of patients. The initial response to
therapy provides a sensitive measure of future clinical outcome.
Measurement of BCR-ABL1 transcript levels using real-time quantitative
polymerase chain reaction standardized to the international reporting
scale is now the principal recommended monitoring strategy. The method
is used to assess early milestone responses and provides a guide for ther-
apeutic intervention. When patients successfully traverse the critical first
12 months of TKI therapy, most will head towards another milestone
response, deep molecular response (DMR, BCR-ABL1 ≤0.01%). DMR is
essential for patients aiming to achieve treatment-free remission and a
prerequisite for a trial of TKI discontinuation. The success of discontinu-
ation trials has led to new treatment strategies in order for more patients
to reach this milestone response. DMR has been incorporated into end-
points of clinical trials and is considered by some expert groups as the
optimal treatment response. But is DMR a stable response and does it pro-
vide the ultimate protection against TKI resistance and death? Do we
need to increase the sensitivity of detection of BCR-ABL1 to better iden-
tify the patients who would likely remain in treatment-free remission
after TKI discontinuation? Is it necessary to switch current TKI therapy to
a more potent inhibitor if the goal is to achieve DMR? These are issues
that I will explore in this review.
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It has been 20 years since the first patients with newly diagnosed chronic
myeloid leukemia (CML) were treated with imatinib in the International
Randomized Study of Interferon and STI571 (IRIS) trial.1 The primary endpoint of
that pivotal trial was the rate of progression, which included death, blast crisis or
accelerated phase, loss of complete hematologic response, loss of major cytogenet-
ic response or an increasing white cell count. Back then, in 2000, response was
measured at the hematologic and cytogenetic levels. How things have changed for
patients diagnosed with CML! Treatment response is now principally monitored
at the molecular level by quantitative measurement of BCR-ABL1 transcripts. 
The prognostic value of molecular monitoring in patients treated with a tyrosine
kinase inhibitor (TKI) was first demonstrated in the IRIS trial.2 The analysis was
exploratory and in general performed only after the achievement of a complete
cytogenetic response. The majority of imatinib-treated patients did indeed achieve
a complete cytogenetic response and the term ‘major molecular response’ (MMR)
was coined. This response was subsequently described as a ‘safe haven’ in which
the risk of loss of response is low.3 The rate of MMR is now a primary or second-
ary outcome measure in CML clinical trials4,5 and is measured on an international
reporting scale (IS) (≤0.1% BCR-ABL1 IS).6 A deep molecular response (DMR,
BCR-ABL1 ≤0.01% IS) is also now an important milestone since it is a prerequisite
for a trial of drug discontinuation with the aim of achieving treatment-free remis-
sion (TFR). The safety of TKI discontinuation for patients
who achieve and maintain a DMR has been demonstrat-
ed in multiple clinical trials7-16 and international expert
groups have incorporated TKI discontinuation into their
recommendations and guidelines.17-20
The majority of CML patients will require lifelong TKI
treatment and long-term molecular monitoring is recom-
mended for all patients with CML.18-20 The European
LeukemiaNet (ELN) mandates measurement of BCR-
ABL1 transcripts according to the IS at least 3 monthly,
even after MMR is confirmed because close monitoring is
required to assess eligibility for TKI discontinuation.19
Most patients will eventually achieve a DMR.21,22 Whether
or not DMR predicts survival has been debated and it has
not been confirmed that it does.22-24 Achieving a sustained
DMR is a prerequisite for TKI discontinuation, but is it
also a biomarker for better clinical outcomes?23,25
Is deep molecular response the optimal molecular
response for patients with chronic myeloid leukemia?
In 2013, the ELN incorporated molecular monitoring
using standardized real-time quantitative polymerase
chain reaction (qRT-PCR) analysis into their recommen-
dations for the management of CML.26 An optimal
response was BCR-ABL1 ≤10%, ≤1% and ≤0.1% at 3, 6
and 12 months of TKI therapy. Treatment failure was
defined as BCR-ABL1 >10% at 6 months and >1% at 12
months. These recommendations were based on strong
evidence collected over many years27-35 and subsequent
studies consolidated the recommendations.36-41 The
importance of a one-log reduction of BCR-ABL1 by 3
months and two-log reduction by 6 months for progres-
sion-free survival was reported as early as 2003.28,29 The
equivalent BCR-ABL1 transcript values on the IS are 10%
and 1%, respectively. An update of molecular data gener-
ated in the IRIS trial was published in 2010, and used to
examine the prognostic significance of early molecular
response.30 Landmark analyses of BCR-ABL1 values at 6,
12 and 18 months of imatinib therapy established that
event-free survival was inferior for patients with >10% at
6 months and >0.1% at 12 and 18 months. Progression to
accelerated phase or blast crisis and overall survival were
inferior for patients with BCR-ABL1 >10% at 6 months,
and >1% at 12 and 18 months.30 In 2012, Hanfstein et al.31
and Marin et al.32 confirmed the strong association
between BCR-ABL1 values at 3, 6 and 12 months and out-
come. Marin et al. reported that the BCR-ABL1 value at 3
months was the only requirement for predicting outcome
for patients treated with a TKI.32 Furthermore, a BCR-
ABL1 value of ≤0.61% at 3 months was highly predictive
of subsequent undetectable BCR-ABL1. The cumulative
incidence of undetectable BCR-ABL1 at 8 years for
patients with BCR-ABL1 ≤0.61% was 84.7% whereas it
was 1.5% for those with >0.61% (P<0.001).32 This study
highlighted the importance of rapid leukemic clearance
for a subsequent DMR.  
The 2013 ELN recommendations for the management
of CML26 were the first time that molecular response was
incorporated into therapeutic decisions by an expert
group, although quite wisely, caution was advised regard-
ing the interpretation of the molecular values. An addi-
tional molecular test was recommended to confirm treat-
ment failure. Numerous publications had confirmed the
predictive value of molecular monitoring,27-35 but most of
the studies had been performed in academic centers with
long-term experience in molecular monitoring. The ELN
recognized that the standard of testing in these studies
may not have represented the typical standard at that
time.  
Widespread incorporation of molecular monitoring for
clinical decisions was made possible by the introduction
of the standardized IS for BCR-ABL1. This was coupled
with harmonization of testing processes, standardization
of the nomenclature for reporting molecular response and
the development of reference material.42-50 The term com-
plete molecular response was replaced by MR4 (BCR-
ABL1 ≤0.01% IS) and MR4.5 (BCR-ABL1 ≤0.0032% IS).47
These terms apply to both detectable and undetectable
BCR-ABL1 and incorporate the sensitivity achieved for
individual samples. However, method standardization
has been challenging and regular molecular monitoring
on the IS is by no means available to all patients because
economic circumstances may hinder its widespread
use.51,52 Nevertheless, molecular monitoring is the princi-
pal recommended monitoring strategy.18-20 Furthermore,
in countries with the most advanced standardized moni-
toring programs, multicenter, high-quality DMR assess-
ment is achievable. This was demonstrated in a recent
study conducted by the European Treatment and
Outcome Study (EUTOS) group in which DMR was
measured reliably by local laboratories in Europe, not just
the key reference laboratories of individual countries.53
There are differences of opinion between experts
regarding the early molecular response milestone values.
Table 1 compares these values between the recent updat-
ed ELN recommendations19 and the National
Comprehensive Cancer Network (NCCN) clinical prac-
tice guidelines.20 The NCCN guidelines  have less strin-
gent BCR-ABL1 cut-off values at 6 months (≤10%) and 12
months (≤1%) for TKI-sensitive disease (no change of
therapy required). The ELN cut-off values for an optimal
response are ≤1% at 6 months and ≤0.1% at 12 months
(no change of therapy required). Furthermore, the ELN
now considers a BCR-ABL1 value of ≤0.01% at any time
as the optimal response for patients aiming for TFR. The
ELN has a buffer response criterion of ‘warning’ between
each milestone BCR-ABL1 cut-off value. A recommenda-
tion in cases of ‘warning’ is additional molecular monitor-
ing if the kinetics of response is not clear. The trend of
BCR-ABL1 decline over time can aid clinical decisions.54,55
The NCCN also suggests assessing the trend of decline
for patients with BCR-ABL1 only slightly >10% at 3
months before making drastic decisions regarding the
treatment strategy. The definition of TKI-resistant disease
after 12 months of TKI therapy is less stringent in the
NCCN guidelines than in the ELN recommendations:
BCR-ABL1 cut-off >10% for the NCCN and >1% for the
ELN (ELN ‘Failure’ category). 
The most recent NCCN guidelines differ from previous
versions in which a BCR-ABL1 value of ≤0.1% at 12
months indicated TKI-sensitive disease.56 The value is
now ≤1% at 12 months and TKI-resistant disease is
defined as >1% at ≥15 months.20 However, the NCCN
still recognizes the value of MMR at 12 months and a
statement is included in the 2020 guidelines: “BCR-ABL1
0.1% at 12 months is associated with a very low proba-
bility of subsequent disease progression and a high likeli-
hood of achieving a subsequent MR4.0, which may facil-
itate discontinuation of TKI therapy.”20
A recent analysis of the German CML-Study IV con-
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firmed the optimal response time to achieve 1% BCR-
ABL1 at about 12 to 15 months for progression-free sur-
vival, with progression being development of accelerated
phase, blast crisis or death.57 The study also investigated
when it is necessary to regard lack of MMR as treatment
failure, indicating that a switch of therapy is warranted.
The landmark time point of 2.5 years to achieve MMR
showed the largest difference between those with or
without MMR with regard to progression-free survival.57
A specific time to achieve DMR for progression-free sur-
vival was not detected. The updated ELN recommenda-
tions now state a change of treatment may be considered
if MMR is not reached by 36-48 months.19
How stable is deep molecular response?
Multiple issues may contribute to loss of a DMR,
including dose reduction, and cessation or non-adherence
to therapy. A rise in BCR-ABL1 levels can be an exquisite
indicator of non-adherence.58 A very rapid rise can indi-
cate complete lack of kinase inhibition due to abrupt TKI
cessation.58 Loss of a DMR is rarely associated with drug
resistance. A recent single-center review of 450 patients
demonstrated that sustained MR4 for at least 12 months
represented a secure response threshold.59 This finding
only applied to compliant patients with no history of pre-
vious TKI resistance who received standard-dose TKI. No
such patient lost a MMR, whereas loss of MMR occurred
in 25% of patients who had not achieved a MR4.
Importantly, failure to sustain a MR4 was the only signif-
icant variable for loss of MMR in multivariate analysis.59
We also found that sustained undetectable BCR-ABL1
(MR4.5) was associated with sustained MMR.21
Conversely, MMR was lost in six of 22 (27%) patients
with sustained detectable BCR-ABL1 and was associated
with the acquisition of imatinib-resistant BCR-ABL1
kinase domain mutations in three of six patients. None of
these three patients had achieved a DMR. Similarly, a
recent study found BCR-ABL1 mutations in 26% of
patients who lost a MMR, although it is not known
whether any of these patients achieved a DMR.60
The molecular response levels use defined cut-off val-
ues and the inherent variability of the quantitative PCR
assay means there will be fluctuations above or below the
cut-off values.61,62 These fluctuations will be greater at low
levels of BCR-ABL1. However, in some cases, fluctuations
are an indication of subsequent relapse. A study of 208
patients treated with imatinib as their first-line therapy
investigated the outcome of patients with fluctuating
BCR-ABL1 values according to the level of response
achieved.63 A stable molecular response was defined as
persistence of the same molecular response (MMR, MR4
or MR4.5) at three consecutive assessments. A fluctuation
was the achievement of the molecular response and its
subsequent loss. For patients who had not yet achieved
DMR but had achieved MMR, 12.6% had at least one
fluctuation. These patients had a significantly poorer fail-
ure-free survival compared to patients with no fluctua-
tion: 82.4% versus 93.2%, respectively. Of patients with
DMR and fluctuations, none acquired resistance or BCR-
ABL1 kinase domain mutations. This study demonstrated
that unstable MMR was associated with an increased risk
of imatinib resistance, whereas fluctuations of deeper
molecular responses did not influence outcome.63
Data suggest that when a DMR is achieved it is rela-
tively stable and the risk of TKI resistance is low.
However, vigilance and long-term molecular monitoring
are recommended, even for patients with stable DMR. A
rare case of late relapse associated with the acquisition of
a BCR-ABL1 kinase domain mutation after long-term, sta-
ble, undetectable BCR-ABL1 (MR4.5) has been reported.64
A Y253H mutation was first detectable by Sanger
sequencing more than 2 years after BCR-ABL1 transcripts
became detectable, which was almost 9 years after com-
mencing imatinib therapy. 
Does real-time quantitative polymerase chain reaction
analysis provide sufficient sensitivity?
Multiple clinical trials have consistently confirmed that
approximately half of the patients who stop TKI in a sta-
ble DMR have molecular recurrence.7-16 Despite many
years having passed since results of the first discontinua-
tion trials were reported, reliable prediction of molecular
relapse has eluded researchers. The NCCN provides crite-
ria for attempting TKI discontinuation, which include sta-
ble MR4 (BCR-ABL1 ≤0.01%) for at least 2 years.20 The
French CML Study Group recommends MR4.5 (BCR-
ABL1 ≤0.0032%) for at least 2 years.17 Although the differ-
ence in BCR-ABL1 levels seems minor, the slow kinetics
of the BCR-ABL1 decline means that MR4.5 may not be
reached until many months, or even years, after MR4.22,65
In the German CML-Study IV the estimated median time
to reach MR4 was 3.1 years, and that to reach MR4.5 was
4.9 years.22 Horn et al. assessed the transcript dynamics of
patients treated with 400 mg imatinib.65 They estimated
that the median time to reach MR4 was 5.3-6.5 years
while that to reach MR4.5 was 9.1-10.7 years. Similarly,
S. Branford
2732 haematologica | 2020; 105(12)
Table 1. Molecular response milestones according to international recommendations and guidelines.
Milestones                        ELN 202019                 NCCN 202020                 ELN 202019               NCCN 202020                 ELN 202019          NCCN 202020
                                            Optimal            TKI-sensitive  disease            Warning                 Possible TKI                     Failure              TKI-resistant 
                                                                                                                                                   resistance                                                   disease
3 months                                      ≤10%                                ≤10%                                 >10%                              >10%                     >10% if confirmed               NA
                                                                                                                                                                                                                         within 1-3 months
6 months                                       ≤1%                                  ≤10%                               >1-10%                               NA                                    >10%                         >10%
12 months                                    ≤0.1%                                 ≤1%                                >0.1-1%                          >1-10%                                 >1%                          >10%
≥15 months                                                                              ≤1%                                                                              NA                                                                         >1%
Any time                             ≤0.1% or ≤0.01%                                                          >0.1-1%, loss                                                         >1%, resistance
                                                  with the aim                                                          of MMR indicates                                                       mutations and 
                                                to achieve TFR                                                        failure after TFR                                                       high-risk ACA                      
ELN: European LeukemiaNet; NCCN: National Comprehensive Cancer Network;  TKI: tyrosine kinase inhibitor; NA: not applicable; TFR: treatment-free remission; MMR: major
molecular response; ACA, additional chromosome abnormalities in Philadelphia-positive cells.
for 528 patients treated with imatinib doses of 400, 600 or
800 mg in the first-line setting, we found an approximate
3-year difference between the times to reach MR4 and
MR4.566 (Figure 1). These studies indicate that the criteria
used for TKI discontinuation significantly influence the
timing of discontinuation.
A recent meta-analysis of 12 TKI discontinuation trials
assessed the factors that influenced the rate of TFR.67
Trials with a molecular criterion of MR4.5 or better for
selecting patients for TKI discontinuation documented
higher rates of TFR at 24 months than those with a cri-
terion of MR4.0: 57.2% versus 50.5%, respectively. This
finding could be associated with the longer treatment
duration needed to achieve MR4.5 or better. Longer
treatment duration is associated with a higher probabil-
ity of sustaining TFR.15 It could also indicate that lower
BCR-ABL1 values before TKI cessation increase the
chance of maintaining TFR. However, Ross et al. failed
to predict TFR using a highly sensitive patient-specific
DNA-based quantitative PCR technique (sensitivity10-
6.2).68 None of the patients studied had detectable BCR-
ABL1 mRNA transcripts, with a sensitivity of MR4.5, at
TKI discontinuation. The DNA technique detected BCR-
ABL1 in almost all patients, irrespective of whether TFR
was maintained or not. Furthermore, DNA BCR-ABL1
continued to be detectable in remission. In a follow-up
of nine patients in long-term TFR, residual DNA BCR-
ABL1 was detected in most patients. In two of these
nine patients, DNA BCR-ABL1 was persistently
detectable at every measurement time-point over 6.5
and 10.5 years, and the level declined over time.69 The
authors hypothesized that this could indicate gradual
extinction of long-lived lineage-committed cells that
lack self-renewal capacity or depletion of slowly prolif-
erating leukemic precursor cells. In a recent analysis that
included the same patients, the lineage of residual
leukemic cells in patients who sustained TFR was inves-
tigated.70 Residual DNA BCR-ABL1 was detected pre-
dominantly in the lymphoid compartment and never in
granulocytes. This was an important finding since the
study demonstrated that the detection of residual BCR-
ABL1 may not imply the persistence of multipotent
leukemic cells. Additionally, lymphocytes were found to
be part of the leukemic clone at the time of diagnosis of
CML and BCR-ABL1 was expressed in both RNA and
DNA. This may have implications for studies in which
T cells are used as a source of non-leukemic cells to
establish the somatic status of variants in next-genera-
tion sequencing studies.71
Digital PCR is being increasingly used to measure resid-
ual BCR-ABL1 DNA and RNA and may improve the pre-
cision and sensitivity of detection.13,72-82 Goh et al.
improved the sensitivity of BCR-ABL1 transcript detec-
tion by pre-amplification prior to digital PCR,72 thereby
introducing a semi-quantitative nested PCR approach.83
Importantly, BCR-ABL1 transcripts were detected by dig-
ital PCR in patients with stable undetectable BCR-ABL1
using the standard qRT-PCR method. This observation
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Figure 1. Time difference between achieving MR4 and MR4.5. We determined
the cumulative incidence of achieving confirmed MR4 and MR4.5 in 528
patients consecutively treated in clinical trials of imatinib. There was an approx-
imate 3-year difference in the median time to reach the deep molecular
response levels in the total cohort. DMR: deep molecular response; CI: confi-
dence interval.
Figure 2. Patients with MR4 at 3 years of
imatinib treatment have a high probability
of reaching MR4.5 with continued imatinib.
Patients without a major molecular
response or MR4 at 3 years of first-line ima-
tinib therapy may benefit from a switch to a
more potent tyrosine kinase inhibitor if the
goal of therapy is to achieve MR4.5.66 MMR:
major molecular response.
corroborates the studies reporting residual DNA BCR-
ABL1 in similar patients’ samples.68,84 
A critical factor for the reliability of data when using
very sensitive PCR is controlling for contamination and
false positive results. This is overcome by quantification
of genomic DNA BCR-ABL1 breakpoints that are unique
to each patient. However, RNA-based techniques are
prone to contamination since common sequences are
amplified for each patient. Negative controls for each
step of the assay are essential to detect contamination
and to establish the threshold for positivity.
Optimization of a digital droplet PCR (ddPCR) method
ensured a background false-positive rate of only 5% of
samples and reliably detected BCR-ABL1 transcripts to
MR5 (0.001%).78 Another group carefully evaluated the
positivity threshold of a ddPCR method by testing 30
samples from non-CML patients.79 The method was used
to measure residual disease in a substantial proportion of
patients enrolled in the Stop Imatinib 2 (STIM2) study
prior to TKI discontinuation. The patients all had unde-
tectable BCR-ABL1 transcripts by qRT-PCR at a sensitiv-
ity level of MR4.5 for at least 2 years. Using the more
sensitive ddPCR method, a cut-off value for detectable
residual disease was established to predict TFR. A con-
version factor to the IS was also established. Patients
with residual BCR-ABL1 levels above the the threshold
of 0.0023% IS had a higher probability of molecular
recurrence at both 6 and 12 months after TKI discontin-
uation: 66% versus 44% and 68% versus 46%, respective-
ly. However, purely on the basis of ddPCR positivity ver-
sus negativity, there was no predictive power for disease
recurrence.79
Whether or not digital PCR can reliably identify the
patients destined for TFR requires further analysis and at
this stage the technique should not be used to select
patients for a TFR attempt.79,85 Key factors for resolution
are harmonization of methods and standardization to the
IS. Importantly, laboratories must ensure that threshold
levels above the background noise are carefully imple-
mented. Furthermore, based on the ddPCR data from the
STIM2 trial,79 Yan et al. estimated that if the ddPCR cut-off
of <0.0023% IS had been added to the STIM2 entry crite-
ria, the rate of TFR at 12 months would have been 54%
instead of the reported 49% for the patients tested by
ddPCR.85 Furthermore, some patients capable of maintain-
ing TFR would be excluded. The authors of the STIM2
ddPCR study clearly stated that this degree of improve-
ment was insufficient for implementation of ddPCR for
selection of patients.79 However, digital PCR may become
an important complement to qRT-PCR in decisions for
attempting TFR, in particular, using a ddPCR method that
reports BCR-ABL1 values on the IS.86
Factors other than the depth of BCR-ABL1 response at
the time of stopping TKI may influence sustained TFR.
The duration of DMR before stopping treatment and
longer duration of therapy were factors in the EURO-SKI
study, which is the largest discontinuation trial.15 The
detection of BCR-ABL1 transcripts using sensitive PCR in
patients with TFR demonstrates that elimination of the
leukemic clone may not be necessary for sustained TFR.72
Immune surveillance may be an important factor.87,88
Sustained MR4.5 is a reasonable molecular response for
a TFR attempt and methods should aim to reliably detect
MR4.5, irrespective of whether the method used is qRT-
PCR or digital PCR.
Strategies to improve the rates of MR4.5  
The first-line use of the second-generation TKI nilotinib
and dasatinib is associated with higher rates of MMR and
MR4.5 than the rates following the use of imatinib and
the responses are achieved earlier.89,90 However, deeper
molecular responses did not translate into improved sur-
vival. Strategies have been explored to induce deeper
molecular responses for imatinib-treated patients, includ-
ing switching to a more potent inhibitor. The ENESTcmr
clinical trial was a randomized study for imatinib-treated
patients in complete cytogenetic response with
detectable BCR-ABL1.91,92 Patients continued on imatinib
or switched to nilotinib 400 mg twice daily. The primary
endpoint of the study was undetectable BCR-ABL1
MR4.5 at 12 months. Higher rates of MMR and MR4.5
were achieved with nilotinib, although adverse events
were more common. The cumulative incidence of MR4.5
following the switch to nilotinib was 32.7% at 12 months
and 42.9% at 24 months.91 The cumulative incidence of
MR4.5 among patients who continued imatinib therapy
was 13.5% and 20.8% at 12 and 24 months, respectively.
Consistent with other trials, cardiovascular events were
more frequent among the nilotinib-treated patients.92 The
potential for improved molecular responses with more
potent TKI must be assessed in light of the potential for
cardiovascular events.93 Furthermore, with the high cost
of second-generation TKI in many countries, the incre-
mental benefit of using these inhibitors to achieve DMR
may not provide good value.94 The ELN had considerable
discussion when revising the recommendations for man-
aging CML in regards to the advisability of using a sec-
ond-generation TKI in the first- or second-line setting to
achieve DMR. However, there was no final consensus.19
We determined whether there was a level of BCR-ABL1
in imatinib-treated patients below which a switch to a
more potent inhibitor may not be necessary in order to
reach a timely MR4.5.66 Among 528 patients consecutive-
ly treated in clinical trials of imatinib, 147 had achieved a
complete cytogenetic response, or its molecular equiva-
lent of ≤1.0% BCR-ABL1,95 at 3 years of imatinib treat-
ment. None of these patients had achieved MR4.5 at that
time. Landmark analyses demonstrated that the patients
without MMR at 3 years of imatinib therapy had a negli-
gible probability of achieving MR4 or MR4.5 with up to
5 additional years of imatinib (Figure 2). These patients
may benefit from a switch to a more potent inhibitor in
order to achieve DMR. Similarly, patients with MMR but
not MR4 at 3 years of imatinib therapy had a significantly
lower cumulative incidence of MR4.5 compared to
patients with MR4: MMR versus MR4, 61% versus 100%
by 5 years after the landmark (P<0.0001). However, most
patients with MR4 at 3 years of imatinib therapy did
indeed achieve MR4.5 with 2 additional years of imatinib
treatment. These findings may help clinical decisions
when considering a switch of treatment to optimize TKI
discontinuation options, while minimizing the additional
risk of adverse events with more potent TKI.
Conclusion
Reaching a DMR is now considered a goal of therapy
by many clinicians. The importance of a DMR for
patients aiming to achieve TFR is recognized by the inclu-
sion of DMR as an endpoint measure in clinical trials.
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Additionally, TFR is increasingly acknowledged as an
avenue to save money in over-stretched healthcare budg-
ets.15,96 However, not all patients and clinicians consider
TFR as the goal of therapy.97 Prolonged survival with min-
imal side-effects are equally important goals and the
patient’s choice is central for treatment decisions. 
The take-home messages from this review are: (i) it can
take many years to reach a DMR for some patients and
earlier achievement is possible with a second-generation
inhibitor; however, there is no consensus on the benefit
of using a second-generation inhibitor to achieve a DMR
and therapy choices must be made in the context of the
individual patient’s comorbidities; (ii) a sustained MR4.5
prior to treatment discontinuation may be associated
with higher rates of TFR than sustained MR4; and (iii)
deeper molecular responses have so far not reliably pre-
dicted TFR. Regardless, sustained DMR is certainly a
desirable outcome since it is associated with an extremely
low risk of loss of response and TKI resistance, and is
mandatory for any patient considering TFR.
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